Structural elucidation of human oxidative metabolites of muraglitazar: Use of microbial bioreactors in the biosynthesis of metabolite standards

Drug Metabolism and Disposition

Volumn 34, Issue 2, 2006, Pages 267-280

  Zhang, Donglu ^a   Zhang, Haiying ^a   Aranibar, Nelly ^a   Hanson, Ronald ^a   Huang, Yande ^a   Cheng, Peter T ^a   Wu, Shung ^a   Bonacorsi, Samuel ^a   Zhu, Mingshe ^a   Swaminathan, Arun ^a   Humphreys, W Griffith ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXY O DEMETHYLMURAGLITAZAR; CARBOXYLIC ACID; DRUG METABOLITE; MURAGLITAZAR; MURAGLITAZAR 12 CARBOXYLIC ACID; MURAGLITAZAR M 1; MURAGLITAZAR M 10; MURAGLITAZAR M 11; MURAGLITAZAR M 13; MURAGLITAZAR M 14; MURAGLITAZAR M 15; MURAGLITAZAR M 16; MURAGLITAZAR M 18; MURAGLITAZAR M 2; MURAGLITAZAR M 3; MURAGLITAZAR M 4; MURAGLITAZAR M 6; MURAGLITAZAR M 7; MURAGLITAZAR M 8; MURAGLITAZAR M 9; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BIOREACTOR; BIOSYNTHESIS; BLOOD SAMPLING; CONTROLLED STUDY; CUNNINGHAMELLA; DEALKYLATION; DEMETHYLATION; DRUG HYDROXYLATION; DRUG ISOLATION; DRUG METABOLISM; DRUG OXIDATION; FECES ANALYSIS; FUNGAL STRAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RADIOACTIVITY; RING OPENING; SACCHAROPOLYSPORA; SACCHAROPOLYSPORA HIRSUTA; TANDEM MASS SPECTROMETRY; URINALYSIS;

BIOREACTORS; BIOTRANSFORMATION; CUNNINGHAMELLA; FECES; GLYCINE; HUMANS; OXAZOLES; OXIDATION-REDUCTION; PPAR ALPHA; PPAR GAMMA; SACCHAROPOLYSPORA;

CUNNINGHAMELLA; CUNNINGHAMELLA ELEGANS; SACCHAROPOLYSPORA; SACCHAROPOLYSPORA HIRSUTA;

EID: 31344457289     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.007153     Document Type: Article

References (22)

1. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Contemporary issues in toxicology. Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
2. Balfour JA, McTavish D, and Heel RC (1990) Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 40:260-290.
3. Balfour JA and Plosker GL (1999) Rosiglitazone. Drugs 57:921-930.
4. Castro-Perez J, Hoyes J, Major H, and Preece S (2002) Advances in MS-based approaches for drug and metabolism studies. Chromatographia 55:S-59.
5. Cheng-Lai A and Levine A (2000) Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Dis 2:326-333.
6. Despres JP (2001) Increasing high-density lipoprotein cholesterol: an update on fenofibrate. Am J Cardiol 88(12A):30N-36N.
7. Devasthale PV, Chen S, Jeon Y, Qu F, Shao C, Wang W, Zhang H, Cap M, Farrelly D, Golla R, et al. (2005) Design and synthesis of N-[(4-methoxyphenoxy) carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy] phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities. J Med Chem 48:2248-2250.
8. Gillies PS and Dunn CJ (2000) Pioglitazone. Drugs 60:333-343 [discussion 344-345].
9. Goldstein BJ (2000) Rosiglitazone. Int J Clin Pract 54:333-337.
10. Ikeda Y, Kondo S, Kanai F, Sawa T, Hamada M, Takeuchi T, and Umezawa H (1985) A new destomycin-family antibiotic produced by Saccharopolyspora hirsuta. J Antibiot (Tokyo) 38:430-438.
11. Mazitschek R, Mulbaier M, and Giannis A (2002) IBX-mediated oxidation of primary alcohols and aldehydes to form carboxylic acids. Angew Chem Int Ed Engl Suppl 41:4059-4061.
12. Mudaliar S and Henry RR (2001) New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52:239-257.
13. Nicolaou KC, Barran PS, and Zhong YL (2001) Selective oxidation at carbon adjacent to aromatic systems with IBX. J Am Chem Soc 123:3183-3185.
14. Packard KA, Backes JM, Lenz TL, Wurdeman RL, Destache C, and Hilleman DE (2002) Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Pharmacotherapy 22:1527-1532.
15. Rosazza JP and Smith RV (1979) Microbial models for drug metabolism. Adv Appl Microbiol 25:169-203.
16. Spencer CM and Barradell LB (1996) Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs 51:982-1018.
17. Yang YF, Zhang DL, and Cerniglia CE (1997) Purification and characterization of a soluble cytochrome P450 enzyme from yeast Trichosporon cutaneum. FEMS Microbiol Lett 154:347-353.
18. Zhang DL, Evans FE, Freeman JP, Duhart B, and Cerniglia CE (1995) Biotransformation of the amitriptyline by Cunninghamella elegans. Drug Metab Dispos 23:1417-1425.
19. Zhang DL, Evans FE, Freeman JP, Yang YF, Deck JD, and Cerniglia CE (1996a) Formation of mammalian metabolites of cyclobenzaprine by the fungus, Cunninghamella elegans. Chem-Biol Interact 102:79-92.
20. Zhang DL, Hansen EB, Deck JD, Heinze TM, Luneau A, Korfmacher WA, and Cerniglia CE (1997) Fungal transformation of antihistamines: metabolism of cyproheptadine hydrochloride by Cunninghamella elegans. Xenobiotica 27:301-315.
21. Zhang DL, Yang YF, Leakey J, and Cerniglia CE (1996b) Phase I and phase II enzyme produced by Cunninghamella elegans for metabolism of xenobiotics. FEMS Microbiol Lett 138:221-226.
22. Zhang HY, Zhang DL, and Ray K (2003) A software filter to remove interference ions from drugs metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J Mass Spectrom 38:1110-1112.